AdAlta Limited announced additional positive pre-clinical data for its lead drug candidate AD-114, a novel first-in-class drug candidate being developed to treat fibrosis, a condition prevalent in 45% to 50% of all diseases. The new data show the administration of AD-114 reduced fibrosis in therapeutic mouse models of both lung and liver fibrosis. In the mouse model of lung fibrosis, collagen deposition and collagen gene expression were both reduced in the lungs, after 14-days of i-body AD-114 treatment. Excessive collagen stiffens tissue, causing fibrosis. In the mouse model of liver fibrosis, serum alanine aminotransferase (ALT) levels and the non-alcoholic fatty liver disease (NAFLD) score were improved with the treatment of AD-114 for 21 days. Concentration of ALT in plasma is a biomarker for liver disease progression: the improvement in serum liver enzyme ALT levels suggests that the i-body ameliorated liver injury and inflammation. The NAFLD score improvement indicates AD-114 possesses hepatoprotective effects and therefore has potential for the treatment of non-alcoholic steatohepatitis (NASH). Extensive pre-clinical AD-114 studies have demonstrated positive in vitro (in the lab) and in vivo (in animals) data. These new data validates a number of earlier studies and AdAlta has now demonstrated anti-fibrotic activity of AD-114 in animal models of lung, liver and eye fibrosis.